TerrAscend Declares its Independence
Common shares to commence trading on the TSX on July 4th with new ticker symbol ‘TSND’TORONTO, June 29, 2023 (GLOBE...
Year: 2023
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor...
Societal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO Services
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process Development, and Clinical Trial Material...
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing...
TScan Therapeutics Announces Transition of Chief Financial Officer
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial...
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A...
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s...
Kineta to Receive $5 Million Milestone Payment from Merck
Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS)SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) --...
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies DT-7012 nominated...
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC...
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
LA JOLLA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...
New research finds Imprivata digital identity solutions accelerated emergency COVID-19 vaccine delivery for Northern Ireland Public Health Service
The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under...
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programsBERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE)...
BioPorto Announces Submission of Response to FDA Additional Information Letter
June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June...
EssilorLuxottica and Jimmy Choo announce a ten-year licensing agreement
EssilorLuxottica and Jimmy Chooannounce a ten-year licensing agreement Charenton-le-Pont, France and London, UK (June 29, 2023 – 8:00 am CEST) –...
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease Sanofi reaffirms ambition to...